View Now | CP-RND: An Introduction to the Patient Community

Hosted by the C-Path team, you can view this recorded webinar to learn more about the Critical Path for Rare Neurodegenerative Diseases public-private partnership.

This webinar and patient-focused roundtable will deliver an enhanced understanding of:

- The CP-RND strategic plan, its stakeholder groups and program deliverables
- The envisioned impact of CP-RND on medical product development in rare neurodegenerative diseases
- Perspectives from patients, regulators and the industry on the public-private partnership and the rare neurodegenerative disease community

Speakers and panelists included:

- **Ronald J. Bartek**
  Co-founder/President,
  Friedreich’s Ataxia Research Alliance

- **Lauren Boak, PhD**
  Lifecycle Leader, GPS NSRD,
  Roche

- **Michelle Campbell, PhD**
  Associate Director, Stakeholder Engagement and Clinical Outcomes,
  U.S. Food and Drug Administration

- **Jacqueline Corrigan-Curay, JD, MD**
  Principal Deputy Center Director,
  Center for Drug Evaluation and Research,
  U.S. Food and Drug Administration

- **Philip Green**
  ALS Patient Advocate

- **Collin Hovinga, PharmD, MS, FCCP**
  Vice President of the Rare and Orphan Disease Programs,
  Critical Path Institute

- **Walter Koroshetz, MD**
  Director, National Institute of Neurological Disorders and Stroke

- **Terina N. Martinez, PhD**
  Executive Director, Critical Path for Rare Neurodegenerative Diseases,
  Critical Path Institute

- **Klaus Romero, MD, MS, FCCP**
  Chief Science Officer;
  Executive Director of Clinical Pharmacology,
  Critical Path Institute

- **Celia Witten, MD, PhD**
  Deputy Director, Center for Biologics Evaluation and Research,
  U.S. Food and Drug Administration